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Multiple substitutions in biologically active domains of 
rabies virus glycoprotein can be related to pathogenic 
profile
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Abstract 
Pathogenic profile of a rabies virus isolated from an insectivorous bat Lasiurus ega was compared with a rabies fixed 
virus strain (CVS/32) in hamster and mouse. Incubation and clinical periods, clinical manifestation and death rates 
were compared. Challenge of hamsters with L. ega was performed using: 10 2,611-4,021 LD50 /0,05 mL;. For CVS were used 
10 3,7-4,7 LD50 /0,05 mL. Were tested intramuscular (IM), intradermal (ID), intranasal (IN), epidermal abrasion (EA) 
inoculation routes. Viral antigen in brains was confirmed by Direct Immunofluorescence Test. Mortality percentages 
observed with L. ega rabies virus isolate were the following in hamster: 3,5 % IM, 10,710% IN; in mice: 50.0% IM, 30.0% 
IN. Furious rabies was predominant. Mortality percentages observed with CVS/32 in hamster: 12.5% IM, 62.5% ID, 
12.5% IN; in mice 100.0% IM, 70.0% ID, 10.0% IN. Paralytic rabies was found with this strain in both animal models. 
Epidermic abrasion was not a suitable challenge route. Incubation period was 5-7 days for CVS and 11-16 days for L. ega 
isolate, meanwhile clinical periods were comprehended between 4–7 days for both viruses. Several substitutions were 
detected at antigenic domains of glycoprotein: AI (position 231), AII (34–42 and 198-200), domain of fusion dependent 
on low pH (102–179), transmembrane domain (440–461) and residue 242. These viruses showed contrasting biological 
behaviors that can be linked to those substitutions at antigenic domains previously described. 
Keywords: Bats. Glycoprotein. Pathogenicity. Phylogeny. Rabies.
Resumo
O perfil patogênico de um vírus da raiva isolado de um morcego insetívoro Lasiurus ega foi comparado com o de vírus 
fixo de raiva (CVS/32) em hamster e camundongo, determinando os períodos de incubação e clínico, manifestação 
clínica e mortalidade. Os animais foram desafiados com 10 2,611 - 4,021 DL50 /0,05 mL do isolado de L. ega e 10 3,7- 4,7 LD50 
/0,05 mL do CVS/32, usando as vias: intramuscular (IM), intradermica (ID), intranasal (IN) e abrasão epidermica (AE). 
A presença do antígeno viral foi confirmada pela prova de imunofluorescência direta. As porcentagens de mortalidade 
observadas com o isolado de L. ega foram as seguintes em hamster: 3,5% IM, 10,71% IN; em camundongo: 50.0% 
IM, 30.0% IN. A forma furiosa da doença foi predominante. As porcentagens de mortalidade observadas com o vírus 
CVS/32 em hamster foram as seguintes: 12.5% IM, 62.5% ID, 12.5% IN; em camundongo 100.0% IM, 70.0%  ID, 
10.0% IN. Com este vírus foi observada raiva paralitica. A via AE mostrou-se inadequada para induzir doença. O 
período de incubação foi de 5–7 dias para o CVS/32 e 11-16 dias para o isolado de L. ega, entre tanto os períodos 
clínicos oscilaram entre 4–7 dias para ambos os vírus. Varias substituições foram achadas em domínios antigênicos da 
glicoproteína: AI (posição 231), AII (34–42 e 198-200), domínio de fusão dependente de baixo pH (102–179), domínio 
da transmembrana (440–461) e resíduo 242. Esses vírus mostraram comportamentos biológicos distintos o que poderia 
estar ligado às substituições nos domínios antigênicos anteriormente descritos.
Palavras-chave: Filogenia. Glicoproteina. Patogenicidade. Quirópteros. Raiva.
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Introduction
Rabies transmission cycle involves terrestrial mam-
mal reservoirs and bats1,2. Control of canine rabies in 
urban centers puts on evidence the growing role of 
chiropterans as transmitters of this disease and other 
related lyssaviruses around the world3,4,5. In the United 
States of America (USA), Canada and Chile several hu-
man cases of rabies involving insectivorous bats as vec-
tors were reported, most of them without a bite history 
or a clear description of the exposition event6,7,8. Mo-
lecular techniques applied to epidemiologic research 
on those cases identified viral lineages from two main 
insectivorous bat species Lasyniocteris noctivagans and 
Tadarida brasiliensis original from USA and Chile re-
spectively9,10. Aminoacid sequence of glycoprotein (a 
viral envelope protein) of L. noctivagans showed sub-
stitutions in domain known as “putative toxic loop”, 
located on residues 190 to 203. This domain is related 
with higher replication efficiency on epidermal cells 
and low invasiveness for central nervous system (CNS) 
by intramuscular challenge11. Other domains of glyco-
protein of CVS virus have been described as relevant 
for pathogenicity in experimental rabies in mice mod-
el. Antigenic site II, residues 102 and 179 as well as resi-
dues 242, 255 and 268 are interrelated and have pro-
found influence on interaction between viral and neu-
ronal receptors and expression of virulence12. Facing 
all the previous information and the lack of knowledge 
regarding to rabies in insectivorous bats, this work was 
intended to study the possible links between pathoge-
nicity and substitutions found on aminoacids sequence 
on active domains of the glycoprotein of a rabies virus 
isolate from Lasiurus ega, an insectivorous bat com-
monly found in proximities to urban areas. 
Material and Method
Viruses
Rabies virus isolate from insectivorous bat Las-
siurus ega, from Presidente Prudente-SP, was kindly 
furnished by Dr. Avelino Albas from Pólo Regional de 
Desenvolvimento Tecnológico dos Agronegócios da 
Alta Sorocabana, Presidente Prudente, SP, Brasil and 
revigorated by three passages in mice. The CVS/32 
fixed rabies virus strain was provided to Faculdade de 
Medicina Veterinária e Zootecnia da USP by the for-
mer Panamerican Zoonoses Center. Argentina. This 
virus was kept frozen at -20 °C, reactivated by five 
passages in mice and used as a pattern for compari-
son to field isolate.
Pathogenicity of L. ega and CVS/32 
For pathogenicity studies, hamster (Mesocricetus 
auratus, without defined lineage) and mice (Mus 
musculus; CH3 – Rockfeller strain) models were used: 
112 hamsters were challenged with L. ega isolate, 64 
with CVS/32 and 40 mice for each one of the viruses. 
Animals were allocated in groups, each group formed 
by 8 – 10 animals, according to inoculation route: in-
tramuscular, intradermal, intranasal and epidermal 
abrasion. Viral titers were calculated by Reed and 
Müench method13, considering confidence intervals 
of 95% for these estimations14. The following viral ti-
ters were used for challenge of hamsters with L. ega 
rabies virus isolate: 2,611 ± 0,610 and 3,831 ± 0,480 
Log 10 LD50 /0,05 mL, only the last dose was tested in 
mice. For CVS were used 3,7 ± 0,525 and 4,7 ± 0,525 
Log10 LD50 /0,05 mL, only the last dose was tested in 
mice. After challenge, experimental animals were 
monitored by 60 days and the incubation and clinical 
periods, predominant clinical manifestations (furi-
ous or paralytic rabies) and mortality percentage were 
recorded. Mortality percentages by inoculation route 
were estimated multiplying the number of deaths by 
100 and dividing for the total of animals challenged 
in each category. Only resulting deaths from chal-
lenge with similar titers were compared. Confidence 
intervals of LD50 estimations were compared using 
figure 1 in order to verify its proximity. Results were 
analyzed through Kruskall - Wallis test using the soft-
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ware MINITAB®, version 15 (2006 Minitab Inc. Lead 
Technologies, Inc), adopting a significance level of 
95%. Rabies virus detection in brains from animals 
with compatible signs of disease was confirmed by 
direct immunofluorescence according Goldwasser 
and Kissling15. This study was approved by Bioethic 
Comission of the School of Veterinary Medicine and 
Animal Science of University of São Paulo under pro-
tocol number 1392/2008.  
Genetic characterization of L. ega isolate and 
CVS/32 strain
After pathogenicity experiments were concluded, 
genetic characterization was performed. The Extrac-
tion of RNA was executed with QIAamp Viral RNA 
kit (QIAGEN, Hilden, Germany). For each 1 ul of 
RNA extracted (equivalent to 0.2 – 0.4 µg of RNA), 
25 µl of 2X SUPERSCRIPT One-Step RT-PCR mix 
(invitrogen, CA, USA) were added. This mix was 
composed by 2 µL of each primer (10 µM), 1,8 µL of 
MgSO4 (50 µM), 1 µl of RT-PCR/Platinum Taq (In-
vitrogen) mix  and 17,2 µL of DEPEC water, to com-
plete a final volume of 50 µL. An initial phase of re-
verse transcription at 50 °C during 60 min., followed 
by 40 PCR cycles at 94 °C for 30 sec., 54 °C for 20 
sec., and 68 °C for 2 minutes, using PTC-0200 ther-
mocycler DNA Engine (MJ Research Inc., Waltham, 
MA, USA)16. RT/PCR and sequencing reactions were 
performed using sense primers Ga3222-4 (5´CGCT-
GCATTTTRTCARAGT3´), GS3994 (5´CGGMTTT-
GTGGATGAAAGRGGC3´) and antisense primers 
(5´GGAGGGCACCATTTGGTMTC3´), Ganti-
BR2072 (5´TGCTGATTGCRCCTACATT3´) target-
ed to the region corresponding to glycoprotein, as pre-
viously described by Sato et al.16. Amplified products 
were confirmed by electrophoreses in 1.5% agarose 
gel, colored with ethidium bromide, cDNA obtained 
were purified with QIAquick Gel Extraction kit (QIA-
GEN, Hilden, Germany). Complete sequences were 
obtained in an automatic sequencer (ABI Prism 3100, 
Applied Biosystems, Foster city, CA, U.S.A), employ-
ing PRISM Dyedeoxy Terminator Cycle sequencing 
Version 2.0 Ready Reaction Kit (Applied Biosystems) 
and Big Dye Terminator Cycle sequencing. Several 
sequencing reactions were performed until obtain se-
quences with at least 60% of bases with quality index 
Figure 1 - Comparison of viral titer estimations including 95% confidence intervals of L. ega rabies 
virus isolate and CVS. Confidence intervals showed overlapping, therefore, viral titers are 
similar
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of 30 or higher. Quality of sequences was evaluated 
using Electropherogram Quality Analysis PHRED 
software, available on http://asparagin.cenargen.em-
brapa.br/phph/, developed by EMBRAPA (Empresa 
Brasileira de Pesquisa Agropecuaria)17,18. A dendro-
gram based on complete glycoprotein gene was con-
structed to establish the phylogenetic relationships of 
virus samples including nucleotide sequences avail-
able on GeneBank. For alignment and edition of se-
quences, the Clustal W software (version 1.83) was 
used. Neighbor-joining method was applied by Mo-
lecular Evolutionary Genetics Analysis -MEGA (ver-
sion 4.1), fixing Kimura -2- evolution model with a 
bootstrap level of 1,000 replications19,20.
Results
Viral pathogenicity
Rabies virus isolate from L. ega showed low mor-
tality in hamster when compared with mice and 
clinical manifestations were predominantly furious, 
only intramuscular and intranasal challenge allowed 
disease development. Two hamsters from the group 
challenged intramuscularly developed paralysia of 
hindlimbs at 16th day post-inoculation, nevertheless 
in a lapse of 24 hours, paralysia resolved without ap-
parent sequelae. CVS induced higher mortality per-
centages in both animal models along with paralytic 
rabies by intramuscular, intranasal and intradermal 
route. There was no spontaneous resolution of rabies 
in this group. It was not possible to induce disease 
using epidermal abrasion with both viruses in the 
animal models studied, see figure 2. Incubation peri-
ods were approximately of 5-7 days for CVS and 11-
16 for L. ega isolate, meanwhile clinical periods were 
comprehended between 4–7 days for the two virus-
es. There was no significant difference in reference 
to these periods. Results of pathogenicity organized 
by inoculation route and viral dose are presented in 
the following order: biological behavior of L. ega ra-
bies virus isolate in hamster and mice model, table 
1; biological behavior of CVS in hamster and mice 
model, table 2.
Animal
Model
Log 10 LD50 /0,05 mL
 ± (I.C 95%) Intramuscular Intradermal Intranasal Epidermal Abrassion
2,611 ± 0,610 0,00 (0/10) 0,00 (0/10) 0,00 (0/10) 0,00 (0/10)
Hamster 3,831 ± 0,480 10,00 (1/10) 0,00 (0/10) 30,00 (3/10) 0,00 (0/10)
4,021 ± 0,53 0,00 (0/8) 0,00 (0/8) 12,5 (1/8) 0,00 (0/8)
Total 3,50 (1/28) 0 (0/28) 10,71 (3/28) 0 (0/28)
Mice 3,831 ± 0,480 50,00 (5/10) 0,00 (0/10) 30,00 (3/10) 0,00 (0/10)
Table 1 - Pathogenicity of L. ega rabies virus isolate in hamster and mice model using similar 
viral doses. Total mortality percentages are presented regarding inoculation 
route and species, fraction in parentheses shows number of fatalities over total of 
challenged animals
Animal
Model
Log 10 LD50 /0,05 mL
 ± (I.C 95%) Intramuscular Intradermal Intranasal Epidermal Abrasion
3,7 ± 0,525 12,5 (1/8) 50,0 (4/8) 12,5 (1/8) 0 (0/8)
Hamster 4,7 ± 0,525 37,5 (3/8) 62,5 (5/8) 12,5 (1/8) 0 (0/8)
 Total 25,00 (4/16) 56,25 (9/16) 6,25 (2/16) 0 (0/16)
Mice 4,7 ± 0,525 100,00 (10/10) 70,00 (7/10) 10,00 (1/10) 0,00 (0/10)
Table 2 - Pathogenicity of CVS in hamster model using similar viral doses. Mortality 
percentages are presented regarding inoculation route and species, fraction in 
parentheses shows number of fatalities over total of challenged animals
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Genetic characterization of L. ega isolate and 
CVS/32
Dendrogram based on nucleotide complete se-
quence of glycoprotein showed segregation between 
isolates corresponding to chiropterans and carni-
vores. L. ega isolate was allocated inside chiropteran 
group with proximity to insectivorous bat clade. 
The CVS/32 virus showed similarity with carnivore 
group, as exposed on figure 3. Aminoacid sequence 
analysis revealed substitutions at antigenic sites as 
AI (aminoacid 231), AII (aminoacids 34–42 and 
198-200), at low pH fusion domain (aminoacids 
102–179) as well as in transmembrane domain (440–
461 aminoacids) and 242 residue. Substitutions were 
illustrated in figure 4.
Discussion 
Results corroborate respiratory system as an en-
trance for rabies transmission by aerosols; neverthe-
less this contamination route is infrequent, being 
the bite transmission more important in nature21,22. 
Airborne transmission is reported only in natural 
environments as caves or under laboratory condi-
tions23. This work suggests the presence of different 
levels of neurovirulence and neuroinvasiviness of ra-
bies virus. Constantine and Woodall24 explored this 
subject for the first time. They studied differences 
between rabies isolates from two insectivorous bat 
species: Eptesicus fuscus and T. brasiliensis, the first 
one did not cause disease after experimental inocu-
lation by intramuscular route in wild and domestic 
carnivores, meanwhile the second one showed vir-
ulence for these species24. In our work, furious ra-
bies induced by L. ega contrasts with the fact that 
rabies isolates from chiropterans frequently induce 
paralytic rabies25,26. Different authors reported that 
furious and paralytic rabies can take place and man-
ifestation of one or another depends on intrinsic 
properties of viral variants27. Differences observed 
on biological behavior of L. ega isolate can be re-
Figure 2 - Mortality percentage according to challenge route for the rabies virus isolate 
from L. ega and CVS/32 fixed strain in hamster and mouse model. Abbreviations: 
I.M = intramuscular; I.N = intranasal; I.D= intradermal
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Figure 3 - Phylogenetic tree of rabies based on 1478 nucleotide sequence of glycoprotein of the rabies virus isolate from L. 
ega and CVS/32 fixed strain. All the rabies of the Americas and other lyssaviruses were obtained from GenBank
lated to viral mechanisms of invasion and migration 
through neurons28. In these processes, cellular mem-
brane receptors are involved as well as viral super-
ficial antigens as glycoprotein29. Transient paralysis 
of the hind-limbs observed in two hamsters from 
group challenged with L. ega isolate by intramus-
cular route could be related to substitutions found 
in glycoprotein sequence, as previously reported by 
Pulmanausahakul et al.30 with a clone from SAD B 19 
strain. Experimental infection in mice with a rabies 
virus expressing a chimeric glycoprotein exchanged 
from an attenuated into a highly pathogenic strain, 
induced a slower viral spread from the spinal cord, 
allowing infection clearance before extensive virus 
replication in the brain, it is possible that similar 
mechanisms of fast viral clearance and slow spread 
are involved in the present experiment30. Mice and 
hamster are both susceptible to rabies virus infec-
tion and have been used extensively as animal mod-
els to study rabies pathogenesis31,32. Results of the 
experiment conducted here suggest that mice are 
more susceptible to rabies than hamster; a possible 
explanation would be related with differences in the 
immune response of both species, since it has been 
documented that animal species respond differently 
to particular antigenic sites on the rabies virus glyco-
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                                         10         20         30         40         50         60         70         80         90        100                            
                                ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
116 L. ega                      EFPIYTIPDK LGPWTPIDIH HLSCPNNLVA ENDGCTSLSG FSYMELKVGY ISAIKVNGFT CTGVVTEAET YTNFVGYVTT TFKRKHFRPM PDACRAAHDW   
CVS/32                          K........E ....S..... .........V .DE...N..E .......... .......... .......... .......... .........T .......YN.   
AB362483 Fox                    K......... ....S..... .........V .DE...N... .......... .......... .......... .......... .........T .......YN.   
M13215 Pasteur Virus            K......... ....S..... .........V .DE...N... .......... .....M.... .......... .......... .........T .......YN.   
AB3831 Insectivorous bat        K......... ....S..... ........IV .DE..S.... .......... .......... .......... .......... .......... .......YN.   
AB383162 Insectivorous bat      K..V...... ....S..... ........IV .DE..NN... .......... .......... .......... .......... .........T .......YN.   
AB383168 E. furinalis           K..V....E. ....S..... ........AV .DE..N.... .......... .......... .......... .......... .......... .......YN.   
RVU52946 L. noctivagans         K......... ....S..... .......... .DE....... .......... .......... .......... .......... .......... ..........   
AB110663 D. rotundus            K......... ....S..... .........V .DE...N... .......... .......... .......... .......... .........I .......YN.   
AB1106664 D. rotundus           K......... ....S..... .........V .DE...N... .......... .......... .......... .......... .........I .......YN.   
AB110658 Dog                    K......... ....S..... .........V .DE...N... .......... .......... .......... .......... .........T .....S.YN.   
AB110656 Cat                    K......... ....S..... .........V .DE...N... .......... .......... .......... .......... .........T .....S.YN.   
AB449206 A. lituratus           K......... ....S..... .........V .DE...N... .......... .......... .......... .......... .........V .......YN.   
AB449207 A. lituratus           K......... ....S..... .........V .DE...N... .......... .......... .......... .......... .........I .......YN.   
EU293116 T. brasiliensis        K......... ....S..... .........V .DE....... .......... .......... .......... .......... .........T .......YN.   
 
                                        110        120        130        140        150        160        170        180        190        200                   
                                ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
116 L. ega                      KMAGDPRYED SLQNPYPDYH WLRTVKTTKE SLVIISPSVA DLDPYDKSLH SRVFPSGKCL GITVSSTYCS TNHDYTIWMP VEPRLGTSCD IFTNSRGKKA   
CVS/32                          .........E ..H....... .....R.... ..I......T .......... .....G...S .......... .......... EN..PR.P.. ........R.   
AB362483 Fox                    .........E ..H....... .......... .......... .......... .........S .......... .......... EN........ ........R.   
M13215 Pasteur Virus            .........E ..H....... .......... .......... ......R... .....G.N.S .VA....... .......... EN....M... ........R.   
AB3831 Insectivorous bat        .........E ..H....... .......... ..I....... .......... ..I..G.... ...I...... .......... E.A....... .....K..R.   
AB383162 Insectivorous bat      .........E ..H....... .......... ..I....... .......... .......... ...I...... .......... EKA....... .....K....   
AB383168 E. furinalis           .........E ..H....... .....T.... ..I....... N......... .....G...M .......F.. .......... ENA....... ...T.K....   
RVU52946 L. noctivagans         .......... .......... .......... .......... .......... .......... .......... .......... ..A....... .....K....   
AB110663 D. rotundus            .........E .......... .......... ..I....... .......... .....G.... .......... .......... E......... ...S.K....   
AB1106664 D. rotundus           .........E .......... .......... ..I....... .......... .....G.... .......... .......... E......... ...S.K....   
AB110658 Dog                    .........E ..H....... .......... .......... .......... .....N...S .......... ........L. EN........ ........R.   
AB110656 Cat                    .........E ..H....... .......... .......... .......... .....N...S .......... ........L. EN........ ........R.   
AB449206 A. lituratus           .........E .......... .......... ..I....... .......... .....G.... .......... .......... E......... ...S.K....   
AB449207 A. lituratus           .........E .......... .......... ..I....... .......... .....G.... .......... .......... E......... ...S.K....   
EU293116 T. brasiliensis        .V.......E .......... .......... ..I....... .......... .......... ...I...... .......... E.A....... .....K....   
 
                                        210        220        230        240        250        260        270        280        290        300                   
                                ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
116 L. ega                      SKGGRVCGFV DERGLYKSLK GACKLKLCGV PGIRLMDGTW VSIQTSEDIK WCPPDRLVNL HDFHSDELEH LVVEELIKRR ENCLDALESI VTTKSVSFRR   
CVS/32                          .N.NKT.... .......... ...R...... L.L....... .AM...DET. .....Q.... ...R...... ......V.K. .E........ M.........   
AB362483 Fox                    ...SKT.... .......... .......... L.L..V.... IAM...DE.. .....Q.... ...R...I.. ......V.K. .E........ ..........   
M13215 Pasteur Virus            ...SET.... .......... .......... L.L....... .AM...NET. ....GQ.... ...R...I.. ......V.K. .E........ M.........   
AB3831 Insectivorous bat        ....KM.... .......... .......... ..L....... ..V..PDET. ..S..Q.... .......I.. ......V.K. .E...T.... M.........   
AB383162 Insectivorous bat      ....K..... .......... .......... ..LT...... ..V..PDEA. .....Q.... .......I.. ......V.K. .E...T.... M.........   
AB383168 E. furinalis           ....KI.... .......... .......... S.L..L.... .T....DE.. .....K.... .......I.. ......VRK. .E...T.... M.........   
RVU52946 L. noctivagans         .....TW... .......... .......... ..L....... ......D... .....Q.... .......I.. ........K. .G........ M.........   
AB110663 D. rotundus            ....KT.... .......... .......... L.L....... ......D.T. .....Q.... .......I.. ......V.K. .E........ M.........   
AB1106664 D. rotundus           .....T.... .......... .......... L.L....... ......D.T. .....Q.... .......I.. ......V.K. .E........ M.........   
AB110658 Dog                    ...SKT.... .......... .......... L.L....... .AM...DET. ..S..Q.... ...R...I.. ......V.K. .E........ M.........   
AB110656 Cat                    ....KT.... .......... .......... L.L....... .AML..DET. .....Q.... ...R...I.. ......V.K. .E........ M.........   
AB449206 A.lituratus            ....KT.... .......... .......... L.L....... ......D.T. .....Q.... .......I.. ......V.K. .E........ M....I....   
AB449207 A.lituratus            ....KT.... .......... .......... L.L....... ......D.T. .....Q.... .......I.. ......V.K. .E........ M.........   
EU293116 T. brasiliensis        .....T.... .......... .......... ..L....... .T....DET. .....Q.... .......I.. ......V.K. .E........ M.........   
 
                                        310        320        330        340        350        360        370        380        390        400                   
                                ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
116 L. ega                      LSHLRKLVPG FGKAYTIFNK TLMEADAHYK SVKTWNEVIP SKGCLEVGGK CHPPVNGVFF NGIILGPDGN VLIPEMQSSL LQQHMELLES SVIPLMHPLA   
CVS/32                          .......... .......... .......... ..R....I.. .....K...R ...H...... ........DH .......... .......... ..........   
AB362483 Fox                    .......... .......... .......... .IR....I.. .....R...R ...H...... .........H .......... .......... ..V.......   
M13215 M13215 Pasteur Virus     .......... .......... .......... ..R....I.. .....R...R ...H...... .......... .......... ........V. ..........   
AB3831 Insectivorous bat        .......... .......... .......... .IQ....... .....K...R ...H.....L .......... .......... .......... .........S   
AB383162 Insectivorous bat      .......... .......... .......... ..H....... .....K...R ...H.....L .......... .......... .......... .........S   
AB383168 E. furinalis           .......... .......... .......... ..N....I.. .....T...R ...H...... .........H .......... .......... ..........   
RVU52946 L. noctivagans         .......... .........N .......... ..R....... .....K...R .......... .......... .......... .......... .....T....   
AB110663 D. rotundus            ..Y....... .......... .......... ..R....I.. .....K.RER .....D.... .......... .......... .......... ..........   
AB1106664 D. rotundus           ..Y....... .......... .......... ..R....I.. ..W..K.RER .....D.... .......... .......... .......... ..........   
AB110658 Dog                    .......... .......... .......... .IR....I.. .....R...R ...H...... .........H .......... .......... ..........   
AB110656 Cat                    .......... .......... .......... .IR....I.. .....R...R ...H...... .........H .......... .......... ..........   
AB449206 A.lituratus            ..Y....... .......... .......... ..R....I.. .....K.RER .....D.... .......... .......... .......... ..........   
AB449207 A.lituratus            ..Y....... .......... .......... ..R....I.. .....K.RER .....D.... .......... .......... .......... ..........   
EU293116 T. brasiliensis        .......... .......... .......... ..R....I.. .....K...R ...H.D.... .......... .......... .......... ..........   
 
                                        410        420        430        440        450        460        470        480        490        500                   
                                ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
116 L. ega                      DPSTVFKEGD EAEDFVEVHL PDVHKQVSDV DLGLPSWGKY LLMSAGALAI LILAIVLIIC CRRVNKTGST QRGHRESRGK MSVAPQNGKI ISSWELYKSE   
CVS/32                          .......... .......... ...Y..I.G. .....N.... V..T...MIG .V.IFS.MTW ...A.RPE.K ..SFGGTG.N V..TS.S..V .P-..S...G   
AB362483 Fox                    .......D.. .....I.... ........G. .....D.... V.....V.IA .M.I.S.MT. ..G.HRPN.I .HRLGGTGR. V..TS.S..V .....S...G   
M13215 Pasteur Virus            .......N.. .......... ....ERI.G. .....N.... V.L.....TA .M.I.F.MT. W....RSEP. .HNL.GTGRE V..T..S... .....S...G   
AB3831 Insectivorous bat        .......D.. .......... ........G. .F...N..R. V......... .M.T.F.M.. ..K.KR.D.S .SSLG.LGR. V..T..S..V .....S....   
AB383162 Insectivorous bat      .......D.. .......... ........G. .F...N..R. V.....V... ...T.F.M.. .....RKDLS RSSLG.LGR. V..T.....V .....S....   
AB383168 E. furinalis           .......D.. .......... ........GI .....N.... V.I...F.VT .L.I.F.M.. ...A.RRV.. .QSLG..GK. VF.I.....V .....S..NG   
RVU52946 L. noctivagans         .......D.. .......... ........EI .......... ......V..T .....F..T. ...A.R.E.. ...R...G.. V......... .........G   
AB110663 D. rotundus            .......... .......... ......I.G. .......... ...I..G..A .V.I.CSMA. ...TKR.E.R R..SG..EK. VTAT..TR.V V.........   
AB1106664 D. rotundus           .......... .......... ......I.G. .......... ...I..G..T .V.I.CSMA. ...TKR.E.R R..SG..EK. VTAT..TR.V V.........   
AB110658 Dog                    .......D.. .......... ........G. .....N.... V.....V.IA .M.T.F.MT. .....RPD.. ..SLGMTGR. V..TS.S..V .....S...G   
AB110656 Cat                    .......D.. .......... ........G. .....N.... V.....V.IA .M.T.F.MT. .....RPD.. ..SLGMTGR. V..TS.S..V .....S...G   
AB449206 A.lituratus            .......... .......... ......I.G. .......... ...I..G..A .V.I.CSMA. ...TKR.E.R R..SG..EK. VTAT..TR.V ..........   
AB449207 A.lituratus            .......... .......... ......I.G. .......... ...I..G..A .V.I.CSMA. ...TKR.E.R R..SG..EK. VTAT..TR.V V.........   
EU293116 T. brasiliensis        .......D.. .......... ......I.G. .....N.... ...I.....G ...I.F.MA. ...AKR.E.R R..SG..ER. VP.P.....V ..........   
                          
                                 
AI 
Domain 
AII 
 Domain AII Domain of fusion dependent on low pH 
Figure 4 - Alignment of aminoacid sequences of glycoprotein from L. ega rabies virus isolate and other sequences 
recovered from Gen Bank. Special distinction has been remarked on substitutions in antigenic sites 
described in the literature
protein33. Immune mechanisms are intimately linked 
to survival and disease processes in rabies infection, 
but other factors interact to define disease outcome 
as pathogenicity of different virus strains, suscepti-
bility of the host and viral dose34,35. We used similar 
viral doses in order to minimize the effect of viral 
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titer variation, so, differences in pathogenic profile 
can be attributed mainly to viral intrinsic properties 
of rabies virus samples analysed here. One of these 
intrinsic characteristics is the degree of glycoprotein 
expression. A well documented case of this scenario 
is CVS/24 strain which is generally pathogenic in 
mice but show different levels of glycoprotein ex-
pression, thus, downregulation of glycoprotein ex-
pression in neuronal cells evidently contributes to 
rabies virus pathogenesis by preventing apoptosis 
and the apparently associated failure of the axonal 
transport nucleoprotein36. In our work, expression 
of glycoprotein of L. ega rabies virus isolate and 
CVS/32 were not measured and compared but cer-
tainly could be a factor with influence on pathogenic 
profiles observed. 
Presence of substitutions on aminoacid sequence 
provides a likely explanation for the unique pathogenic 
profile of L. ega rabies isolate. This hypothesis is based 
on the presence of substitutions on glycoprotein do-
mains with biological importance for rabies virus as 
AI (aminoacids 218-231), AII (aminoacids 34–42 and 
198-200), low pH fusion domain (aminoacids 102–179) 
as well as in transmembrane domain (440–461 amino-
acids) and residue 24237. These regions were identified 
by monoclonal antibodies and were designated as anti-
genic sites with implications in pathogenicity and im-
munogenicity. AI site acts as conformational and linear 
antigen and apparently is highly conserved through 
lyssavirus genus; this may be explained by the presence 
of a cystein residue which is involved in glycoprotein 
folding. The analysis of about 200 sequences of rabies 
virus glycoprotein, with special attention to residue 231 
(AI site), showed that leucine has a 70,7% of frequency 
at this position, followed by proline with 26,7%. The 
second aminoacid was found in L. ega rabies virus iso-
late studied here. The same substitution was found in 
the Lasyniocteris noctivagans isolate from North Amer-
ica and maybe is responsible for its pathogenic profile 
concomitantly with substitution on 333 residue8,38.
Antigenic site II, comprehending residues at positions 
34 to 42 and 198 to 200, is involved in recognition of 
nervous terminations. Selection of mutant strains ex-
hibiting punctual mutations in this region was per-
formed with monoclonal antibodies. When mice were 
challenged with strains exhibiting mutation on the 
four residues, there was a reduction in pathogenicity of 
300%. A reduction of 10 to 30% in pathogenicity was 
achieved when strains only possessed a couple of mod-
ifications in two of the aforementioned set of residues39. 
The low pH-induced fusion domain in the G protein 
is believed to be located between amino acids 102 and 
179. This domain interacts with endosomal membrane 
inside the host cell, resulting in the ejection of rabies 
virus ribonucleoprotein into the cytoplasm, triggering 
life cycle of rabies virus40. At least three aminoacids on 
positions 242, 255 and 268 of glycoprotein were iden-
tified as necessary for pathogenicity of Nishigahara 
strain of rabies virus12. Experiments with induced mu-
tants remarked the relevance of substitutions on posi-
tion 268. Nevertheless, a combination of modifications 
on the three aforementioned positions is necessary for 
a total virulence reversion, resulting in reduced rates 
of cellular invasion in vitro12. The transmembrane do-
main (aa´s 439–461) is an anchor for trimeric spikes of 
glycoprotein, these projections extend 8.3 nm from the 
virus surface providing structure to viral envelope and 
cooperates in folding process of the mature protein41. 
Influence on pathogenicity of substitutions at this level 
are unknown but is well documented that transmem-
brane domain besides to glycoprotein ectodomain 
elicit a strong humoral response, inducing neutralizing 
antibodies42. There is not literature discussing the con-
sequences in pathogenicity associated to mutations in 
the region between residues 390 and 504. This region 
is included in the glycoprotein ectodomain (residues 
1-439) that portion is responsible for virus interaction 
of rabies virus with its cellular binding sites (receptors) 
and therefore is important in viral pathogenesis. It is 
critical to the host immune response to rabies virus 
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infection because it is responsible for the induction of 
neutralizing antibodies, being a target for virus specific 
helper and cytotoxic T cells41.
Literature is abundant in the analysis of antigenic 
variation of rabies virus and remarks its implications 
on vaccines effectiveness as well as post-exposition 
treatment. Cases of vaccine failure were correlated with the 
degree of antigenic disparity between the vaccine and challenge 
viruses, as revealed by analysis with monoclonal antibodies43. 
Conclusions
Pathogenicity of rabies virus is a complex charac-
teristic that involves antigenic variation (related to 
linear and conformational epitopes), viral dose, ex-
position route and immune response of the host. 
Glycoprotein is one of the most important deter-
minants of pathogenicity of rabies virus since is the 
only structure exposed on the surface that interacts 
directly with the immune system of the host. Con-
formational modifications and mutations on primary 
structure as well as level of expression of glycopro-
tein have a major impact on pathogenicity. Moreover 
“hidden” components as pH-dependent fusion and 
transmembrane domain, triggers viral life cycle and 
transynaptic spread. It is important to keep in mind 
that pathogenicity is a multigenic trait, nucleoprotein, 
phosphoprotein, matrix protein and viral polymerase 
work coordinately in viral life cycle and interactions 
with host cell. With these considerations in mind it is 
possible to suggest that substitutions described in this 
work may be related with pathogenic profile observed 
in mice and hamster model.  
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